Ton Schumacher Group

Molecular Oncology & Immunology

Our Focus

There is now abundant clinical evidence that the T cell-based immune system can control the growth of human cancers. My ambition is three-fold: 1). To develop novel technologies that can be utilized to understand how T cells recognize and destroy human cancers; 2). To exploit these technologies to reveal the mode of action of clinically used immunotherapies; 3). To use the resulting knowledge to design more specific and more effective immune interventions. Over the past years, a major focus of our work has been to understand which tumor antigens play a central role in the clinical activity of present-day cancer immunotherapeutics. With this knowledge reaching the stage where biotech development forms the logical next step, our subsequent goal is to help crack the code that determines the specificity of TCRs reactive against tumor antigens and other antigens.

Björn Kwee Bioinformatician
Connor Richterich Phd Student
Jos Urbanus Analyst
Marius Messemaker Phd Student
Rana N. Ozdeslik Sahilioglu Postdoctoral Researcher
Contact Information
Ton Schumacher

Ton Schumacher

Oncode Investigator

Oncode Investigator

More Research

Research Strategy
Focus and Approach
Over 800 scientists working under a single strategy. Oncode is all about uniting efforts and bringing focus to research.
Support Programme
Our supporting programmes
New plans that help fulfil Oncode's objectives get our full support. Young talents are matched with mentors on the basis of their personal endeavours.